AXS-07 is a novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine. AXS-07 consists of MoSEIC™ (Molecular Solubility Enhanced Inclusion Complex) meloxicam and rizatriptan.

AXS-07 is an investigational drug not yet approved by the FDA.

clinical and regulatory

AXS-07 is currently being developed for the acute treatment of migraine.